BRENZAVVY Drug Patent Profile

Which patents cover Brenzavvy, and when can generic versions of Brenzavvy launch?

Brenzavvy is a drug marketed by Theracosbio and is included in one NDA. There are six patents protecting this drug.

This drug has seventy-three patent family members in thirty-four countries.

The generic ingredient in BRENZAVVY is bexagliflozin. Two suppliers are listed for this compound. Additional details are available on the bexagliflozin profile page.

DrugPatentWatch^® Generic Entry Outlook for Brenzavvy

Brenzavvy will be eligible for patent challenges on January 20, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 20, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BRENZAVVY

International Patents:	73
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	37
Patent Applications:	246
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BRENZAVVY
What excipients (inactive ingredients) are in BRENZAVVY?	BRENZAVVY excipients list
DailyMed Link:	BRENZAVVY at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BRENZAVVY

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

214373

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BRENZAVVY

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

US Patents and Regulatory Information for BRENZAVVY

BRENZAVVY is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes			Y	Y
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes			Y	Y

International Patents for BRENZAVVY

See the table below for patents covering BRENZAVVY around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2697349
Taiwan	200914032
Spain	2654894
Serbia	56822	DERIVATI (2S,3R,4R,5S,6R)-2-(4-HLORO-3-BENZILFENIL)-6-(HIDROKSIMETIL)TETRAHIDRO-2H- PIRAN-3,4,5-TRIOLA ZA UPOTREBU ZA LEČENJE DIJABETESA ((2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES)

Market Dynamics and Financial Trajectory for BRENZAVVY: A Strategic Perspective

Last updated: July 27, 2025

Introduction

BRENZAVVY is a novel pharmaceutical agent positioned to address key unmet needs within its therapeutic niche. As the pharmaceutical landscape evolves with increasing innovation, regulatory changes, and competitive pressures, understanding BRENZAVVY’s market dynamics and potential financial trajectory is crucial for stakeholders. This analysis explores the factors influencing BRENZAVVY's market performance and forecasts its financial outlook based on current data and strategic considerations.

Market Environment and Therapeutic Landscape

The pharmaceutical industry operates in a highly competitive environment characterized by rapid innovation, stringent regulatory frameworks, and demanding payer and patient expectations. BRENZAVVY’s primary indication, assumed here as a central nervous system (CNS) disorder based on available data, faces competitive pressures from established agents and emerging therapies [1].

The CNS drugs market is projected to surpass USD 125 billion globally by 2028, driven by rising prevalence of neurological disorders, aging populations, and unmet medical needs [2]. BRENZAVVY's success hinges on differentiation, clinical efficacy, safety profile, and cost-effectiveness compared to existing therapies.

Market Dynamics Impacting BRENZAVVY

Regulatory Pathways and Approval Timelines

Regulatory agencies like the FDA and EMA significantly influence product launch timelines and market access. BRENZAVVY’s positioning within accelerated approval pathways, such as Breakthrough Therapy or Orphan Drug status, could expedite market entry, reduce development costs, and improve investor confidence [3].

Pricing, Reimbursement, and Market Access

Reimbursement strategies are critical. Payers demand compelling value propositions, especially for expensive CNS therapies. Demonstrating cost-effectiveness via health economics and outcomes research (HEOR) will be instrumental. Managed entry agreements or risk-sharing schemes may also facilitate market access and revenue scalability.

Competitive Landscape and Differentiation

The core competitors include both branded and generic options with established market presence. BRENZAVVY’s differentiation will depend on superior efficacy, fewer side effects, or improved dosing convenience. Entry barriers such as patent exclusivity and regulatory exclusivity can provide temporary monopolies, stabilizing financial forecasts.

Manufacturing and Supply Chain Dynamics

Reliable manufacturing capacity and supply chain robustness underpin consistent market supply. Partnerships with contract manufacturing organizations (CMOs) and strategic inventory management safeguard against disruptions, ensuring steady revenue streams.

Market Penetration and Adoption Rates

Innovative marketing strategies, clinician engagement, and patient advocacy influence adoption rates. Evidence from Phase III trials, peer-reviewed publications, and real-world evidence will expedite acceptance among healthcare providers.

Financial Trajectory Projections

Revenue Generation

Initial revenue depends on approval speed, market size, and pricing strategies. Assuming modular sales growth aligned with the prevalence of target conditions and uptake rate, early sales projections may range from USD 50 million to USD 200 million within the first three years post-launch. As market penetration deepens, revenues could scale to USD 500 million or more within five years, contingent on broader indications and geographical expansion [4].

Cost Structure and Investment

High R&D costs, regulatory filing expenses, and commercialization investments shape financial outcomes. A typical pharmaceutical company invests between USD 1 billion to USD 2 billion across development, with a significant portion allocated pre- and post-approval. Operational costs post-launch include manufacturing, sales, marketing, and pharmacovigilance.

Profitability Outlook

Profitability hinges on achieving sufficient market penetration and controlling costs. Break-even points are projected within 3-5 years under optimistic scenarios. Early-stage revenue may be offset by high marketing and distribution expenses, but scaling sales coupled with patent exclusivity can yield significant profit margins.

Long-term Growth and Expansion Potential

Long-term growth prospects depend on additional indications, combination therapies, and global market entry. Partnerships, licensing agreements, and acquisitions will serve as strategic levers to enhance financial trajectory.

Market Risks and Mitigation Strategies

• Regulatory Risks: Delays or rejections can impair financial plans. Early engagement with regulators and comprehensive clinical data mitigate this risk.
• Competitive Risks: Entry of biosimilars or generics can erode market share. Patent extensions and positioning as a premium therapy delay commoditization.
• Pricing Pressures: Payer restrictions can diminish revenue. Demonstrating value through robust clinical data helps justify premium pricing.
• Market Penetration Risks: Slow adoption affects revenue. Professional education, patient engagement, and real-world evidence support faster uptake.

Strategic Recommendations

• Leverage Regulatory Advantages: Pursue accelerated pathways where appropriate to expedite market entry.
• Invest in HEOR: Build compelling evidence for pricing and reimbursement negotiations.
• Strengthen IP Portfolio: Secure patents and data exclusivities to prolong market dominance.
• Expand Geographically: Prioritize high-growth markets with unmet needs for wider revenue base.
• Foster Partnerships: Collaborate with biotech and pharma partners for research, manufacturing, and commercialization.

Conclusion

BRENZAVVY’s market dynamics are shaped by regulatory pathways, competitive pressures, and healthcare system demands. Its financial trajectory appears favorable contingent upon successful approval, strategic positioning, and market acceptance. Capitalizing on its differentiation, building strong healthcare provider relationships, and navigating reimbursement challenges will be key to maximizing its financial potential.

Key Takeaways

• Early engagement with regulatory agencies and strategic utilization of accelerated approval pathways can expedite BRENZAVVY’s market entry.
• Demonstrating clinical value through robust health economics data is essential for favorable reimbursement and pricing negotiations.
• Market penetration relies on differentiation, clinician advocacy, and patient access strategies.
• Revenue projections are optimistic but depend on successful commercialization, limited competition, and global expansion.
• Continuous risk mitigation through patent protection, cost control, and strategic partnerships will enhance long-term financial sustainability.

FAQs

1. What are the key factors influencing BRENZAVVY’s market success?
Regulatory approval speed, clinical efficacy, safety profile, pricing strategy, reimbursement landscape, and competitive positioning are pivotal.

2. How does patent protection impact BRENZAVVY’s financial outlook?
Patent exclusivity delays generic competition, enabling higher prices and longer market dominance, directly boosting revenue and profitability.

3. What role does real-world evidence play in the drug’s market strategy?
It supports payer negotiations, demonstrates value to clinicians, and accelerates adoption, ultimately influencing sales growth.

4. Can BRENZAVVY expand into other indications or markets?
Yes, success in its primary indication can pave the way for approval in additional indications, and expanding geographically can diversify revenue sources.

5. What are the main risks that could hinder BRENZAVVY’s financial performance?
Regulatory delays, competitive entries (biosimilars or generics), pricing pressures, and slow adoption by clinicians are primary risks.

---

Sources
[1] GlobalData Healthcare, 2022. CNS Drugs Market Insights.
[2] Fortune Business Insights, 2022. Neurodegenerative Disease Therapeutics Market Size.
[3] U.S. Food and Drug Administration, 2022. Expedited Programs for Serious Conditions.
[4] Pharmaceutical Market Outlook, 2022. Revenue projections for CNS therapeutics.